REFERENCES
1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
3. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
4. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024;65:100485.
5. Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62:2915-22.
6. Younossi ZM, Stepanova M, Al Shabeeb R, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 2024;8:e0352.
7. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158:1611-25.e12.
8. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557-65.
9. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362-73.
10. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-54.e1-9.
11. Simon TG, Roelstraete B, Hagström H, Loomba R, Ludvigsson JF. Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study. J Hepatol. 2023;79:1366-73.
12. Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology. 2019;70:1913-27.
13. Schattenberg JM, Balp MM, Reinhart B, et al. Identification of fast progressors among patients with nonalcoholic steatohepatitis using machine learning. Gastro Hep Adv. 2024;3:101-8.
14. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78.e5.
15. Patel NS, Doycheva I, Peterson MR, et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:561-8.e1.
16. Patel NS, Hooker J, Gonzalez M, et al. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15:463-4.
17. Koutoukidis DA, Jebb SA, Tomlinson JW, Cobbold JF, Aveyard P. Association of weight changes with changes in histological features and blood markers in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2022;20:e538-47.
18. Malespin MH, Barritt AS 4th, Watkins SE, et al. Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort. Clin Gastroenterol Hepatol. 2022;20:2393-5.e4.
19. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157-66.
20. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255-66.
21. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460-8.
22. Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66:142-52.
23. Vitaglione P, Morisco F, Mazzone G, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010;52:1652-61.
24. Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:e8-12.
25. Liu F, Wang X, Wu G, et al. Coffee consumption decreases risks for hepatic fibrosis and cirrhosis: a meta-analysis. PLoS One. 2015;10:e0142457.
26. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016;43:562-74.
27. Bravi F, Tavani A, Bosetti C, Boffetta P, La Vecchia C. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev. 2017;26:368-77.
28. Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38:2552-7.
29. Zhang S, Fu J, Zhang Q, et al. Association between nut consumption and non-alcoholic fatty liver disease in adults. Liver Int. 2019;39:1732-41.
30. Chen BB, Han Y, Pan X, et al. Association between nut intake and non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults. BMJ Open. 2019;9:e028961.
31. Semmler G, Bachmayer S, Wernly S, et al. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. PLoS One. 2020;15:e0244514.
32. Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N, et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol. 2018;68:1239-46.
33. Abdelmalek MF, Suzuki A, Guy C, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961-71.
34. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17:374-444.
35. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919.
36. Semmler G, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD/NASH: beyond the obvious. Liver Int. 2021;41:2249-68.
37. Darmon N, Drewnowski A. Contribution of food prices and diet cost to socioeconomic disparities in diet quality and health: a systematic review and analysis. Nutr Rev. 2015;73:643-60.
38. Moriya A, Iwasaki Y, Ohguchi S, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol. 2015;62:921-7.
39. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57:384-91.
40. Hashimoto Y, Hamaguchi M, Kojima T, et al. Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J Gastroenterol Hepatol. 2015;30:546-52.
41. Kwon I, Jun DW, Moon JH. Effects of moderate alcohol drinking in patients with nonalcoholic fatty liver disease. Gut Liver. 2019;13:308-14.
42. Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:129-35.
43. Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64-75.
44. Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18:1831-41.e5.
45. Åberg F, Puukka P, Salomaa V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71:835-48.
46. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81:930-40.
47. Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38:485-521.
48. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
49. Sanyal AJ, Chalasani N, Kowdley KV, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
50. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71:495-509.
51. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549-56.
52. Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702.
53. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-57.
54. Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, et al. Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related, child-pugh a cirrhosis. Clin Gastroenterol Hepatol. 2021;19:136-45.e6.
55. Zhou J, Ke Y, Lei X, et al. Meta-analysis: the efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. Ann Hepatol. 2020;19:320-8.
56. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307.
57. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176-84.
58. Majzoub AM, Nayfeh T, Barnard A, et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021;54:880-9.
59. Armstrong MJ, Gaunt P, Aithal GP, et al; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90.
60. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46:100-9.
61. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637-49.
62. Newsome PN, Buchholtz K, Cusi K, et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113-24.
63. Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54:1150-61.
64. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60:1525-33.
65. Loomba R, Hartman ML, Lawitz EJ, et al; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.
66. Loomba R, Abdelmalek MF, Armstrong MJ, et al; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511-22.
67. Peverelle M, Ng J, Peverelle J, Hirsch RD, Testro A. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World J Gastroenterol. 2023;29:6165-7.
68. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
69. Harrison SA, Loomba R, Dubourg J, Ratziu V, Noureddin M. Clinical trial landscape in NASH. Clin Gastroenterol Hepatol. 2023;21:2001-14.
70. Institute for Clinical and Economic Review. Non-Alcoholic Steatohepatitis. An assessment of resmetirom and obeticholic acid for NASH. Available from: https://icer.org/assessment/non-alcoholic-steatohepatitis-2023/. [Last accessed on 23 Dec 2024].
71. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-85.
72. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964-73.
73. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397:293-304.
74. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-76.
75. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014;370:2002-13.
76. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-51.
77. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. JAMA. 2013;309:2240-9.
78. Ikramuddin S, Korner J, Lee WJ, et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA. 2018;319:266-78.
79. Lim WH, Lin SY, Ng CH, et al. Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals. Hepatobiliary Surg Nutr. 2023;12:658-70.
80. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290-301.e5.
81. Pais R, Aron-Wisnewsky J, Bedossa P, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology. 2022;76:456-68.
82. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401:1786-97.
83. Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:897-901.
84. Shimizu H, Phuong V, Maia M, et al. Bariatric surgery in patients with liver cirrhosis. Surg Obes Relat Dis. 2013;9:1-6.
85. Diwan TS, Rice TC, Heimbach JK, Schauer DP. Liver transplantation and bariatric surgery: timing and outcomes. Liver Transpl. 2018;24:1280-7.
86. Safwan M, Collins KM, Abouljoud MS, Salgia R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 2017;23:1415-21.
87. Idriss R, Hasse J, Wu T, et al. Impact of prior bariatric surgery on perioperative liver transplant outcomes. Liver Transpl. 2019;25:217-27.
88. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22:281-91.
89. Widmer J, Eden J, Abbassi F, et al. How best to combine liver transplantation and bariatric surgery? Liver Int. 2024;44:566-76.
90. Campsen J, Zimmerman M, Shoen J, et al. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg. 2008;18:1625-7.
91. Tariciotti L, D'Ugo S, Manzia TM, et al. Combined liver transplantation and sleeve gastrectomy for end-stage liver disease in a bariatric patient: first European case-report. Int J Surg Case Rep. 2016;28:38-41.
92. Nesher E, Mor E, Shlomai A, et al. Simultaneous liver transplantation and sleeve gastrectomy: prohibitive combination or a necessity? Obes Surg. 2017;27:1387-90.
93. Heimbach JK, Watt KD, Poterucha JJ, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013;13:363-8.
94. Zamora-Valdes D, Watt KD, Kellogg TA, et al. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology. 2018;68:485-95.
95. Dayyeh BK, Bazerbachi F, Graupera I, Cardenas A. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease. J Hepatol. 2019;71:1246-8.
96. Bustamante-Bernal MA, Chavez LO, Zuckerman MJ. Endoscopic bariatric interventions in patients with chronic liver disease. Clin Liver Dis. 2022;26:139-48.
97. Singh S, Hourneaux de Moura DT, Khan A, Bilal M, Ryan MB, Thompson CC. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2020;16:340-51.
98. Aoko O, Maharaj T, Boland F, Cheriyan D, Ryan J. Meta-analysis: impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity. Aliment Pharmacol Ther. 2024;59:8-22.
99. Espinet Coll E, Vila Lolo C, Díaz Galán P, et al. Bariatric and metabolic endoscopy in the handling of fatty liver disease. A new emerging approach? Rev Esp Enferm Dig. 2019;111:283-93.
100. Jagtap N, Kalapala R, Katakwar A, et al. Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity. Indian J Gastroenterol. 2021;40:572-9.
101. Hajifathalian K, Mehta A, Ang B, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc. 2021;93:1110-8.
102. Bazerbachi F, Vargas EJ, Rizk M, et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021;19:146-54.e4.
103. Li AA, Kim D, Ahmed A. Association of Sarcopenia and NAFLD: an overview. Clin Liver Dis. 2020;16:73-6.
104. Zhao Q, Yin Y, Deng Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study. Nutr Diabetes. 2023;13:21.
105. Tarantino G, Sinatti G, Citro V, Santini SJ, Balsano C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Intern Emerg Med. 2023;18:1887-95.
106. Tagliafico AS, Bignotti B, Torri L, Rossi F. Sarcopenia: how to measure, when and why. Radiol Med. 2022;127:228-37.
107. Bhanji RA, Narayanan P, Moynagh MR, et al. Differing impact of Sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease. Liver Transpl. 2019;25:14-24.
108. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14:1870-9.
109. Xu CQ, Mohamad Y, Kappus MR, et al. The relationship between frailty and cirrhosis etiology: from the functional assessment in liver transplantation (FrAILT) study. Liver Int. 2021;41:2467-73.
110. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-53.
111. Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol. 2019;71:313-22.
112. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188-95.
113. Yong JN, Lim WH, Ng CH, et al. Outcomes of nonalcoholic steatohepatitis after liver transplantation: an updated meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2023;21:45-54.e6.
114. Minich A, Arisar FAQ, Shaikh NS, et al. Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: a systematic review and meta-analysis. EClinicalMedicine. 2022;50:101534.
115. Diaz-Nieto R, Lykoudis PM, Davidson BR. Recipient body mass index and infectious complications following liver transplantation. HPB. 2019;21:1032-8.
116. Giorgakis E, Tedeschi M, Bonaccorsi-Riani E, et al. The effect of recipient body mass index and its extremes on survival and graft vascular and biliary complications after liver transplantation: a single center retrospective study. Ann Transplant. 2017;22:611-21.
117. Goldaracena N, Cullen JM, Kim DS, Ekser B, Halazun KJ. Expanding the donor pool for liver transplantation with marginal donors. Int J Surg. 2020;82S:30-5.
118. Lim WH, Ng CH, Tan D, et al. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023;79:1015-24.
119. O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol. 2011;9:700-4.e1.
120. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-55.
121. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161:1887-95.e4.
122. Linares I, Hamar M, Selzner N, Selzner M. Steatosis in liver transplantation: current limitations and future strategies. Transplantation. 2019;103:78-90.
123. Andert A, Ulmer TF, Schöning W, et al. Grade of donor liver microvesicular steatosis does not affect the postoperative outcome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2017;16:617-23.
124. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16:874-84.
125. Dutkowski P, Schlegel A, Slankamenac K, et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256:861-8.
126. Croome KP, Lee DD, Taner CB. The “Skinny” on assessment and utilization of steatotic liver grafts: a systematic review. Liver Transpl. 2019;25:488-99.
127. Jackson KR, Motter JD, Haugen CE, et al. Temporal trends in utilization and outcomes of steatotic donor livers in the United States. Am J Transplant. 2020;20:855-63.
128. Kwong AJ, Kim WR, Lake J, et al. Impact of donor liver macrovesicular steatosis on deceased donor yield and posttransplant outcome. Transplantation. 2023;107:405-9.
129. Lascaris B, de Meijer VE, Porte RJ. Normothermic liver machine perfusion as a dynamic platform for regenerative purposes: what does the future have in store for us? J Hepatol. 2022;77:825-36.
130. Patrono D, De Carlis R, Gambella A, et al. Viability assessment and transplantation of fatty liver grafts using end-ischemic normothermic machine perfusion. Liver Transpl. 2023;29:508-20.
131. Goldaracena N, Barbas AS. Living donor liver transplantation. Curr Opin Organ Transplant. 2019;24:131-7.
132. Cotter TG, Minhem M, Wang J, et al. Living donor liver transplantation in the United States: evolution of frequency, outcomes, center volumes, and factors associated with outcomes. Liver Transpl. 2021;27:1019-31.
133. Bhangui P, Sah J, Choudhary N, et al. Safe use of right lobe live donor livers with up to 20% macrovesicular steatosis without compromising donor safety and recipient outcome. Transplantation. 2020;104:308-16.
134. Neil DAH, Minervini M, Smith ML, Hubscher SG, Brunt EM, Demetris AJ. Banff consensus recommendations for steatosis assessment in donor livers. Hepatology. 2022;75:1014-25.
135. Tien C, Remulla D, Kwon Y, Emamaullee J. Contemporary strategies to assess and manage liver donor steatosis: a review. Curr Opin Organ Transplant. 2021;26:474-81.
136. Tejedor-Tejada J, Valenzuela EF, Muñoz RN, et al. De-novo nonalcoholic fatty liver disease at 5-years after liver transplantation: prevalence and predictive factors. Eur J Gastroenterol Hepatol. 2021;33:399-406.
137. Silva AC, Nogueira P, Machado MV. Hepatic steatosis after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2023;29:431-48.
138. Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. Transplantation. 2019;103:e345-54.
139. Galvin Z, Rajakumar R, Chen E, et al. Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis. Liver Transpl. 2019;25:56-67.
140. Kim H, Lee KW, Lee K, et al. Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients. Hepatol Res. 2018;48:E162-71.
141. Satapathy SK, Tran QT, Kovalic AJ, et al. Clinical and genetic risk factors of recurrent nonalcoholic fatty liver disease after liver transplantation. Clin Transl Gastroenterol. 2021;12:e00302.
142. Taneja S, Roy A, Duseja A. NASH after liver transplantation: impact of immunosuppression. J Clin Exp Hepatol. 2023;13:835-40.
143. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American association for the study of liver diseases and the american society of transplantation. Liver Transpl. 2013;19:3-26.
144. Mikolasevic I, Stojsavljevic S, Blazic F, et al. Noninvasive markers of liver steatosis and fibrosis after liver transplantation - where do we stand? World J Transplant. 2021;11:37-53.
145. Ng CH, Tan DJH, Lim XC, et al. A diagnostic test meta-analysis evaluating imaging-based and blood biomarker-based assessment tools for fibrosis after liver transplantation. Liver Transpl. 2022;28:659-69.
146. Pissaia A Jr, Borderie D, Bernard D, Scatton O, Calmus Y, Conti F. APRI and FIB-4 scores are useful after liver transplantation independently of etiology. Transplant Proc. 2009;41:679-81.
147. Kabbany MN, Conjeevaram Selvakumar PK, Guirguis J, et al. Accuracy of noninvasive fibrosis scores in predicting the presence of fibrosis in patients after liver transplantation. Exp Clin Transplant. 2018;16:562-7.
148. Bhat M, Ghali P, Rollet-Kurhajec KC, et al. Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. Liver Transpl. 2015;21:1383-94.
149. Germani G, Laryea M, Rubbia-Brandt L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation. Transplantation. 2019;103:57-67.
150. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212-9.
151. Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: a meta-analysis. PLoS One. 2017;12:e0185192.
152. Siddiqui MS, Idowu MO, Stromberg K, et al. Diagnostic performance of vibration-controlled transient elastography in liver transplant recipients. Clin Gastroenterol Hepatol. 2021;19:367-74.
153. Deurdulian C, Grant EG, Tchelepi H, et al. Assessment of fibrosis in liver transplant recipients: diagnostic performance of shear wave elastography (SWE) and correlation of SWE findings with biopsy results. AJR Am J Roentgenol. 2019;213:W264-71.
154. Singh S, Venkatesh SK, Keaveny A, et al. Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: a pooled analysis. Ann Hepatol. 2016;15:363-76.
155. Choudhury A, Singh SP, Desmukh A, Sahoo B, Eslam M. Post-liver transplant metabolic syndrome. J Clin Exp Hepatol. 2024;14:101368.
156. Pisano G, Donato MF, Consonni D, et al. High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. Dig Liver Dis. 2020;52:84-90.
157. Hüsing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. World J Gastroenterol. 2016;22:3315-24.
158. VanWagner LB, Holl JL, Montag S, et al. Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients. Am J Transplant. 2020;20:797-807.
159. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662-9.
160. Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019;15:172-88.
161. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23:739-49.
162. Schwaiger E, Krenn S, Kurnikowski A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial. J Am Soc Nephrol. 2021;32:2083-98.
163. Pena JM, Cusi K. Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia. J Clin Endocrinol Metab. 2023;109:e1-11.
164. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-85.
165. Kukla A, Hill J, Merzkani M, et al. The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients. Transplant Direct. 2020;6:e524.
166. Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. Diabetes Obes Metab. 2019;21:1061-5.
167. Thangavelu T, Lyden E, Shivaswamy V. A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation. Diabetes Ther. 2020;11:987-94.
168. Tsamalaidze L, Stauffer JA, Arasi LC, et al. Laparoscopic sleeve gastrectomy for morbid obesity in patients after orthotopic liver transplant: a matched case-control study. Obes Surg. 2018;28:444-50.
169. Morris MC, Jung AD, Kim Y, et al. Delayed sleeve gastrectomy following liver transplantation: a 5-year experience. Liver Transpl. 2019;25:1673-81.
